Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1626 1627
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18007776 | RIPK1 INHIBITORS AND METHODS OF USE | Final Rejection | Merck Sharp & Dohme LLC |
| 18028311 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | Final Rejection | The Regents of the University of California |
| 18022017 | BIOINSPIRED LIPID DERIVATIVES AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | Final Rejection | Novartis AG |
| 18035478 | RAF INHIBITOR FOR TREATING LOW GRADE GLIOMA | Final Rejection | Dana-Farber Cancer Institute Inc. |
| 18532710 | NOVEL CRYSTALLINE FORMS OF 1-(4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE, SALT FORMS THEREOF, AND PROCESSES TO OBTAIN | Non-Final OA | Merck Patent GmbH |
| 18557236 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM |
| 18001074 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER | Final Rejection | ETH ZÜRICH |
| 18880793 | SURFACE TREATMENT METHOD, SEQUENCING METHOD, AND KIT | Non-Final OA | GeneMind Biosciences Co., Ltd. |
| 18084092 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | Final Rejection | Janssen Pharmaceutica NV |
| 17917538 | COMPOSITIONS AND METHODS TO INHIBIT FOULING OF AMMONIUM SALTS | Non-Final OA | ECOLAB USA INC. |
| 18020025 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | Non-Final OA | CORNELL UNIVERSITY |
| 18020019 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | Non-Final OA | CORNELL UNIVERSITY |
| 17769307 | METHODS OF INHIBITING LIVER-TYPE GLUTAMINASE, GLS2 | Non-Final OA | CORNELL UNIVERSITY |
| 18265740 | SMALL MOLECULES AS LARP1 LIGANDS | Final Rejection | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18285650 | METHODS FOR OPTIMIZING THE TREATMENT OF COLORECTAL CANCER | Non-Final OA | Brown University |
| 18015657 | SUBSTITUTED 4-(3-AMINOPROP-1-YL)AMINOQUINOLINE ANALOGS AS MODULATORS OF MELANOMA-ASSOCIATED ANTIGEN 11 UBIQUITIN LIGASE | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 17872533 | SEPARATION OF RARE EARTH METALS | Final Rejection | The Queen's University of Belfast |
| 18468907 | C19 SCAFFOLDS AND STEROIDS AND METHODS OF USE AND MANUFACTURE THEREOF | Non-Final OA | Trustees of Dartmouth College |
| 18268688 | DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS | Final Rejection | BioCryst Pharmaceuticals, Inc. |
| 17921369 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | Non-Final OA | Lonza Greenwood LLC |
| 18021784 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | Non-Final OA | Betta Pharmaceuticals Co., Ltd. |
| 18522917 | HETEROCYCLIC COMPOUND AND USE THEREOF | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18004532 | SULFONYLBENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| 18251729 | COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF | Non-Final OA | TYK MEDICINES, INC. |
| 18005165 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. |
| 18015616 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18561797 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY ALVEOLAR PROTEINOSIS RELATED TO MARS MUTATIONS | Non-Final OA | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) |
| 18558806 | POLO LIKE KINASE 4 INHIBITORS | Non-Final OA | ORIC Pharmaceuticals, Inc. |
| 18558810 | NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF | Non-Final OA | UNIVERSITA' DI PISA (40%) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy